March 18, 2016 / 11:01 AM / 4 years ago

BRIEF-Eagle Pharmaceuticals says FDA rejects company's blood thinner

March 18 (Reuters) - Eagle Pharmaceuticals Inc :

* Eagle Pharmaceuticals receives complete response letter from FDA on Kangio (RTU Bivalirudin) application

* Says FDA requested further characterization of Bivalirudin related substances in drug product

* Eagle Pharmaceuticals Inc says Eagle will work directly with FDA to determine an appropriate path forward

* Eagle Pharmaceuticals Inc says evaluating FDA’s response Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below